INVIVYD SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. - IVVD, ADGI
INVIVYD SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. - IVVD, ADGI
NEW ORLEANS, March 10, 2023 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until April 3, 2023 to file lead plaintiff applications in a securities class action lawsuit against Invivyd, Inc. (the "Company") (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. ("Adagio") (NasdaqGM: ADGI), if they purchased the Company's shares between November 29, 2021 and December 14, 2021, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Massachusetts.
Get Help
Invivyd investors should visit us at or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
About the Lawsuit
Invivyd and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On December 14, 2021, the Company (then named Adagio) disclosed that in vitro test results for ADG20, its lead product candidate against the COVID-19 Omicron variant, revealed that it was 300 times less effective at neutralizing Omicron than it was against the other variants, despite assuring investors of the efficacy against Omicron only a few weeks prior.
On this news, shares of Adagio plummeted nearly 80%, from $34.26 per share on December 13, 2021, to $7.26 per share when the market closed on December 14, 2021.
The case is Brill v. Invivyd, Inc., No. 23-cv-10254.
About ClaimsFiler
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit .
SOURCE ClaimsFiler
新奧爾良,2023年3月10日/美通社/--免費股東資訊服務公司ClaimsFeller提醒投資者,他們有2023年4月3日在針對Invivyd,Inc.(納斯達克股票代碼:IVVD)f/k/a Adagio Treateutics,Inc.(納斯達克股票代碼:ADGI)的證券集體訴訟中提出主要原告申請,前提是他們在2021年11月29日和2021年12月14日,包括(“上課時間”)。此操作在中掛起美國香港特區地方法院馬薩諸塞州.
尋求幫助
Invivyd投資者應致電或撥打免費電話(844)367-9658訪問我們。Kahn Swick&Foti,LLC的律師可以為您討論法律選擇。
關於這起訴訟
Invivyd及其某些高管被控在Class期間未能披露重要資訊,違反了聯盟證券法。
在……上面2021年12月14日,該公司(當時名為Adagio)披露,其針對新冠肺炎奧密克戎變體的主要候選產品ADG20的體外測試結果顯示,它對奧密克戎的中和效果是對其他變體的300倍,儘管幾周前還向投資者保證了它對奧密克戎的有效性。
受此消息影響,Adagio的股價暴跌近80%,34.26美元上的每股2021年12月13日,至7.26美元收盤時的每股收益2021年12月14日.
情況是這樣的布裡爾訴因維維德公司。,編號23-cv-10254。
關於ClaimsFeller
ClaimsFeller的使命只有一個:作為資訊來源,幫助散戶投資者從證券集體訴訟和解中追回他們數十億美元的份額。在ClaimsFiler.com上,投資者可以:(1)免費註冊,獲得各種證券集體訴訟案件的資訊和和解網站,以便他們可以及時提交自己的索賠;(2)上傳他們的投資組合交易數據,以便獲得有關他們可能有經濟利益的相關證券案件的通知;以及(3)向Kahn Swick&Foti律師事務所提交查詢,以進行免費的案件評估。
要了解有關ClaimsFeller的更多資訊,請訪問。
源聲明檔案管理器
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧